^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TNFA-L

i
Other names: Tumor Necrosis Factor, Tumor Necrosis Factor Ligand Superfamily Member 2, Cachectin, TNF-Alpha, TNFSF2, TNF-A, TNFA, Tumor Necrosis Factor (TNF Superfamily, Member 2), Tumor Necrosis Factor Ligand 1F, Tumor Necrosis Factor-Alpha, TNF Superfamily, Member 2, TNF Macrophage-Derived, TNF Monocyte-Derived, APC1 Protein, TNLG1F
Entrez ID:
Related biomarkers:
3ms
Malondialdehyde and TNF-α lowering effects of purified gambier (Uncaria gambir Roxb.) in diabetic rats. (PubMed, J Ayurveda Integr Med)
These results depicted that at doses of 2.5-10 mg/kg BW, purified gambier has antioxidant-associated anti-inflammation effects when given for 14 days on diabetic rat model by reducing plasma levels MDA and TNF-α.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
TNFA-L
7ms
Analysis of cerebral Interleukin-6 and tumor necrosis factor alpha patterns following different ventilation strategies during cardiac arrest in pigs. (PubMed, PeerJ)
The results indicate that chest compression synchronized ventilation may have a potential positive impact on the cytokine expression levels post-resuscitation. Further studies are needed to derive potential therapeutic algorithms from these findings.
Journal
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
|
TNFA-L
1year
Tumour necrosis factor-alpha levels as predictor factor on clinical response of anthracycline-based neoadjuvant chemotherapy in locally advance breast cancer patients: experimental research. (PubMed, Ann Med Surg (Lond))
Participants received anthracycline-based neoadjuvant chemotherapy (cyclophosphamide of 500 mg/m, doxorubicin of 50 mg/m and fluorouracil/5FU of 500 mg/m) for 3 cycles. The statical analysis showed a significant association of TNF-α levels on the clinical response of chemotherapy, which showed r=-0.606 and P<0.001. TNF-α levels predict clinical response for anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha)
|
TNFA-L
|
5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide
over2years
Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: In vitro and in vivo studies. (PubMed, Tumour Biol)
CUR-NAR-D-MNPs used alone had a certain therapeutic effect on tumors. CUR-NAR-D-MNPs plus radiotherapy significantly reduced the tumor volume and led to cell cycle arrest and induction of apoptosis through modulation of P53high, P21high, TNF-αlow, CD44low, and ROShigh signalingCUR-NAR-D-MNPs are effective in the treatment of tumors when combined with radiotherapy, and show radiosensitization effects against cancer proliferation in vitro and in vivo.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CD44 (CD44 Molecule)
|
TNFA-L
3years
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13). (PubMed, Cytokine)
Further, we designed a risk score with TGF-β1, TNF-α, and IFN-γ levels, which could prognosticate patients for PFS. In conclusion, serum cytokine level, such as TGF-β1, TNF-α, and IFN-γ, could be a potential prognostic biomarker for breast cancer patients with bone metastasis treated with ZA and taxane-based chemotherapy.
Clinical • Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FGF2 (Fibroblast Growth Factor 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
TNFA-L
|
zoledronic acid